Related references
Note: Only part of the references are listed.High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss
Mahamadou Bassirou Souleymane et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?
Sabira Tahseen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies
Dumessa Edessa et al.
PLOS ONE (2021)
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
Gabriela Beatriz Gomez et al.
BMJ OPEN (2021)
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Camus Nimmo et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements
Alberto Piubello et al.
RESPIRATORY MEDICINE (2020)
Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
Arnaud Trebucq et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Tuberculosis treatment: one-shot approach or cascade of regimens?
Tom Decroo et al.
Lancet Respiratory Medicine (2020)
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda
J-C S. Ngabonziza et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2020)
Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives
Zibusiso Ndlovu et al.
LANCET HIV (2020)
Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
Francois Ciza et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
Tom Decroo et al.
PLOS ONE (2020)
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Andrew J. Nunn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations
L. Rigouts et al.
SCIENTIFIC REPORTS (2019)
The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy
Alexandra Calmy et al.
CLINICAL INFECTIOUS DISEASES (2018)
Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs
A. Van Deun et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2018)
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries
A. Trebucq et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2018)
Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015
Miranda G. Loutet et al.
EMERGING INFECTIOUS DISEASES (2018)
Early Mortality during Initial Treatment of Tuberculosis in Patients Co-Infected with HIV at the Yaounde Central Hospital, Cameroon: An 8-Year Retrospective Cohort Study (2006-2013)
Jean Joel R. Bigna et al.
PLOS ONE (2015)
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Armand Van Deun et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Share Paper
